Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 20/20 | 1.00 |
| ▸ | PSEN2 | P49810 | 20/20 | 1.00 |
| ▸ | APH1B | Q8WW43 | 20/20 | 1.00 |
| ▸ | NCSTN | Q92542 | 20/20 | 1.00 |
| ▸ | APH1A | Q96BI3 | 20/20 | 1.00 |
| ▸ | PSENEN | Q9NZ42 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16198584 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL16452768 | 0.89 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL16198583 | 0.88 | PSEN1 (0.78) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12298488 | 0.85 | PSEN1 (0.77) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL652801 | 0.80 | PSEN1 (0.67) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12074506 | 0.80 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL15069926 | 0.78 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12072821 | 0.78 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12074513 | 0.78 | PSEN1 (0.66) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12298495 | 0.78 | PSEN1 (0.64) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281638-A1 | Compositions and Methods for Activating Natural Killer Cells | CHIMERA BIOENGINEERING, INC. (US) | 2025-09-11 | — | — | US | claimed |
| CN-118207152-A | Culture solution capable of promoting growth and improving functions of vascular endothelial stem cells | 张易 | 2024-06-18 | — | — | CN | claimed |
| US-20230118517-A1 | METHODS OF TREATING MULTIPLE MYELOMA | SEAGEN INC. | 2023-04-20 | — | — | US | claimed |
| WO-2022260968-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING NATURAL KILLER CELLS | CHIMERA BIOENGINEERING, INC. (US) | 2022-12-15 | — | — | WO | claimed |
| CN-114874973-A | Culture medium and culture method for obtaining mature hepatocytes | 深圳市三启生物技术有限公司 | 2022-08-09 | — | — | CN | claimed |
| WO-2022125392-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING T-CELLS | CHIMERA BIOENGINEERING, INC. (US) | 2022-06-16 | — | — | WO | claimed |
| US-12589109-B2 | Therapy to stimulate hippocampal neural progenitors and adult neurogenesis | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2026-03-31 | — | — | US | disclosed |
| US-12576135-B2 | Compositions and methods for anti-TnMUC1 gold CAR t-cells | CHIMERA BIOENGINEERING, INC. | 2026-03-17 | — | — | US | disclosed |
| US-20250344963-A1 | METHODS FOR ACQUIRING AND ANALYZING NEUROMELANIN-SENSITIVE MRI | UNIV OF OTTAWA INSTITUTE OF MENTAL HEALTH RESEARCH (CA) | 2025-11-13 | — | — | US | disclosed |
| US-20250302864-A1 | METHODS FOR TREATING ALZHEIMER’S DISEASE | CYCLO THERAPEUTICS INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250281638-A1 | Compositions and Methods for Activating Natural Killer Cells | CHIMERA BIOENGINEERING, INC. (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250195477-A1 | DEUTERATED IDAZOXAN AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC. | 2025-06-19 | — | — | US | disclosed |
| CN-120051284-A | Methods for treating early stage Alzheimer's disease | 赛克洛治疗股份有限公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20220175776-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | Frequency Therapeutics, Inc. (US) | 2022-06-09 | — | — | US | disclosed |
| US-11337631-B2 | Methods and magnetic imaging devices to inventory human brain cortical function | Brainn F.I.T. Imaging, LLC (US) | 2022-05-24 | — | — | US | disclosed |
| CN-114340611-A | Combination of CHIR99021 and valproic acid for the treatment of hearing loss | 频率医疗公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2022051631-A1 | THERAPY TO STIMULATE HIPPOCAMPAL NEURAL PROGENITORS AND ADULT NEUROGENESIS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2022-03-10 | — | — | WO | disclosed |
| WO-2022040447-A2 | METHODS FOR TREATING RESPIRATORY DISEASES CHARACTERIZED BY MUCUS HYPERSECRETION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20220057403-A1 | MODULATING BIOMARKERS SUCH AS SPP TO INCREASE TUMOR IMMUNITY AND IMPROVE THE EFFICACY OF CANCER IMMUNOTHERAPY | DANA-FARBER CANCER INSTITUTE, INC. | 2022-02-24 | — | — | US | disclosed |
| EP-3952854-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | Frequency Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589109-B2 | Therapy to stimulate hippocampal neural progenitors and adult neurogenesis | DCX, PSEN1, CSNK1D | PSEN1 2/4885PSEN2 7/4885APH1B 218/4885 |
| US-12576135-B2 | Compositions and methods for anti-TnMUC1 gold CAR t-cells | BRCA1, RNASE1, NSUN2 | PSEN1 1270/4885PSEN2 2445/4885APH1B 4192/4885 |
| US-20250302864-A1 | METHODS FOR TREATING ALZHEIMER’S DISEASE | PSEN2, PSEN1, ACHE | PSEN1 2/4885PSEN2 1/4885APH1B 197/4885 |
| US-20220175776-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | HES1, SHH, HDAC11 | PSEN1 98/4885PSEN2 45/4885APH1B 63/4885 |
| US-20250195477-A1 | DEUTERATED IDAZOXAN AND METHODS OF USE THEREOF | XDH, INA, SLC6A3 | PSEN1 124/4885PSEN2 169/4885APH1B 1169/4885 |
| US-20230118517-A1 | METHODS OF TREATING MULTIPLE MYELOMA | GSAP, MGAM, CD22 | PSEN1 238/4885PSEN2 609/4885APH1B 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.